65,437 trials
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2 · Obesity
Primary: Glomerular Filtration Rate (GFR) Under Euglycaemic Conditions After 4 Weeks of Treatment With Either Empagliflozin Added to Ramipril or Placebo Added to Ramipril…
Cholestasis
Primary: Part A- Area Under the Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC[0-t]) for Total-OCA at Steady State: OCA Arm — 2329.804…
Chronic Rhinitis
Primary: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE) — 0 Participants
Chronic Rhinosinusitis · Endoscopic Sinus Surgery · Chronic Rhinosinusitis Without Polyps
Primary: Sino-nasal Outcome Test (SNOT-22) Over Time — 43.8; 42.9; 39.7; 38.5 score on a scale — p=0.819
Malaria, Vivax
Primary: Percentage of Participants With Relapse-free Efficacy at Six Months After Administration of Tafenoquine With DHA-PQP and DHA-PQP Alone — 12; 22 Percentage of…
Healthy Volunteers
Primary: Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings — -0.1; -0.6; -0.1; 0.1 ms
Cardiovascular Disease
Primary: Number of Subjects With Major Adverse Cardiovascular Events — 170; 167 participants — p=0.91
Attention Deficit Hyperactivity Disorder · ADHD
Primary: Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task — 79.08; 79.43; 77.98; 78.24 percent correct inhibition
Infantile Spasms
Primary: Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs) — 6 Participants
HIV-1 Infection
Primary: Number of Participants With Virologic Rebound at 8 Weeks After Interruption of Antiretroviral Therapy — 4; 3 Participants
Recurrent Breast Carcinoma · Stage IV Breast Cancer
Primary: PFS — 3.5 months
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Chronic Inflammatory Demyelinating Polyneuropathy
Primary: Number of Participants With Survival — 66; 64 Participants
Vascular Cognitive Impairment no Dementia
Primary: Estimated Mean Change of the Montreal Cognitive Assessment (MoCA) — 3.356; -0.085 score on a scale
Nausea
Primary: Nausea 100 mm Visual Analogue Scale (VAS) — 23; 19; 42 units on a scale